Prevalence of metabolic and hematologic manifestations among women with polycystic ovarian syndrome
Paper Details
Prevalence of metabolic and hematologic manifestations among women with polycystic ovarian syndrome
Abstract
Polycystic Ovarian Syndrome (PCOS) is a prevalent endocrine disorder that significantly affects women’s health, but its impact on women remains overlooked. In this study, various metabolic and hematologic tests were performed, with the aims: (1) determine test results of metabolic parameters: (a) fasting blood sugar (FBS), (b) total cholesterol, (c) blood urea nitrogen (BUN), & (d) creatinine; and (2) hematologic parameters: (e) hematocrit (Hct), (f) hemoglobin (Hb), (g) prothrombin time (PT), & (h) activated partial thromboplastin time (aPTT) among PCOS-diagnosed women. As well as to (3) determine the significant relationship between the date of PCOS diagnosis with the metabolic and hematologic parameters. The group consists of 10 PCOS-diagnosed women Ten (10), 18-35-year old women, medically diagnosed with PCOS by a physician in City of San Fernando, La Union. Statistical analysis revealed that the mean total cholesterol of the respondents are interpreted as “high” and are therefore more likely to exhibit abnormally elevated total cholesterol levels more than FBS, BUN and creatinine. They are also more likely to exhibit normal hematologic parameters, such as Hct, Hb, PT, and aPTT. It was also pointed out that there is no significant relationship between the date of diagnosis of PCOS and the metabolic and hematologic parameters in PCOS-diagnosed women. Thus, regardless of the time of diagnosis of PCOS, it does not actually affect their metabolic and hematologic manifestations. This study posits that PCOS-diagnosed women are likely to have affected metabolic functions more than hematologic functions.
Al Kafhage FA, Abbas AN, Al-Masaoodi RA, Hassan S, Al-Shemery MK. 2023. The relationship between hormonal levels and hematological parameters in cystic ovarian syndrome. Journal of Medicine and Life 16(6), 937–940. https://doi.org/10.25122/jml-2022-0315
Alhabardi NA, Al-Wutayd O, Eltayieb KM, Shiha YS, Al-Shafei AI, Adam I. 2020. Peripheral hematological parameters in women with polycystic ovary syndrome. Journal of International Medical Research 48(9), 1–6. https://doi.org/10.1177/0300060520952282
Auvinen J, Tapio J, Karhunen V, Kettunen J, Serpi R, Dimova EY, Gill D, Soininen P, Tammelin T, Mykkänen J, Puukka K, Kähönen M, Raitoharju E, Lehtimäki T, Ala-Korpela M, Raitakari OT, Keinänen-Kiukaanniemi S, Järvelin MR, Koivunen P. 2021. Systematic evaluation of the association between hemoglobin levels and metabolic profile implicates beneficial effects of hypoxia. Science Advances 7(29), eabi4822. https://doi.org/10.1126/sciadv.abi4822
Barath B, Varga A, Matrai AA, Deak-Pocsai K, Nemeth N, Deak A. 2022. Estradiol valerate affects hematological and hemorheological parameters in rats. Metabolites 12, 602. https://doi.org/10.3390/metabo12070602
Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R. 2006. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clinical Pharmacology and Therapeutics 80(2), 105–114. https://doi.org/10.1016/j.clpt.2006.03.014
Berthelot MPE. 1859. Berthelot’s reaction mechanism. Report de Chimie Applique 2884.
Bhat A. 2023. Descriptive research: Characteristics, methods + examples. QuestionPro. https://www.questionpro.com/blog/descriptive-research/
Bishop ML, Fody EP, Schoeff LE. 2013. Clinical chemistry: Principles, techniques, and correlations, 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
Bisquera NA, Dampil OA, Mendoza E, Manalo-Mendoza Y. 2023. Comparison of cardio-metabolic parameters between the different polycystic ovary syndrome phenotypes among Filipino women in a tertiary hospital. Journal of the ASEAN Federation of Endocrine Societies 38(3), 29–30. https://asean-endocrinejournal.org/index.php/JAFES/article/view/3233
Bulanov NM, Suvorov AY, Blyuss OB, Munblit DB, Butnaru DV, Nadinskaia MY, Zaikin AA. 2021. Basic principles of descriptive statistics in medical research. Sechenov Medical Journal 12(3), 4–16. https://doi.org/10.47093/2218-7332.2021.12.3.4-16
Chan T. 2022. How menopause affects cholesterol and how to manage it. Healthline. https://www.healthline.com/health/menopause/cholesterol-and-menopause
Chang KJ, Chen JY, Chen KH. 2024. The pathophysiological mechanism and clinical treatment of polycystic ovary syndrome: A molecular and cellular review of the literature. International Journal of Molecular Sciences 25(16), 9037. https://doi.org/10.3390/ijms25169037
Chen MA. 2024. Lipid profile test. MedlinePlus. https://medlineplus.gov/ency/article/007812.htm
Chen W, Pang Y. 2021. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites 11, 869. https://doi.org/10.3390/metabo11120869
Cho M, Kim S, Chun S. 2023. Relationship between hematologic parameters related to systemic inflammation and insulin resistance-associated metabolic parameters in women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine 50(3), 206-212. https://doi.org/10.5653/cerm.2023.05932
Cleveland Clinic. 2021. Fasting blood sugar test. https://my.clevelandclinic.org/health/diagnostics/21952-fasting-blood-sugar
Cleveland Clinic. 2023. Partial thromboplastin time. https://my.clevelandclinic.org/health/diagnostics/25101-partial-thromboplastin-time
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. 2008. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism 93(3), 914–919. https://doi.org/10.1210/jc.2007-1692
Cunha JP. 2019. Creatinine blood tests. eMedicineHealth. https://www.emedicinehealth.com/creatinine_blood_tests/article_em.htm
El-Eshmawy MM, Ibrahim A, Bahriz R, Shams-Eldin N, Mahsoub N. 2022. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women. BMC Endocrine Disorders 22, 315. https://doi.org/10.1186/s12902-022-01240-y
Escobar-Morreale HF. 2018. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24
Dave R. Abenoja, Christian L. Almazan, Shanlynn Pauline G. Aniceto, Mark Ericson B. Baladad, Avrille Vrynt C. Basila, Jenica Dennise A. Galleta, Ristian Aaron T. Lubiano, 2025. Prevalence of metabolic and hematologic manifestations among women with polycystic ovarian syndrome. Int. J. Biomol. Biomed., 20(3), 13-31.
Copyright © 2025 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.